vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and SentinelOne, Inc. (S). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $258.9M, roughly 1.2× SentinelOne, Inc.). MADRIGAL PHARMACEUTICALS, INC. runs the higher net margin — -18.2% vs -23.3%, a 5.0% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 22.9%). SentinelOne, Inc. produced more free cash flow last quarter ($20.9M vs $-133.8M).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

SentinelOne, Inc. is an American cybersecurity company listed on NYSE based in Mountain View, California. The company was founded in 2013 by Tomer Weingarten, Almog Cohen and Ehud ("Udi") Shamir. Weingarten acts as the company's CEO. The company has approximately 2,800 employees and offices in Mountain View, Boston, Prague, Tokyo, and Tel Aviv. The company uses machine learning for monitoring personal computers, IoT devices, and cloud workloads. The company's platform utilizes a heuristic mod...

MDGL vs S — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.2× larger
MDGL
$321.1M
$258.9M
S
Growing faster (revenue YoY)
MDGL
MDGL
+187.9% gap
MDGL
210.8%
22.9%
S
Higher net margin
MDGL
MDGL
5.0% more per $
MDGL
-18.2%
-23.3%
S
More free cash flow
S
S
$154.8M more FCF
S
$20.9M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
MDGL
MDGL
S
S
Revenue
$321.1M
$258.9M
Net Profit
$-58.6M
$-60.3M
Gross Margin
73.8%
Operating Margin
-18.6%
-28.3%
Net Margin
-18.2%
-23.3%
Revenue YoY
210.8%
22.9%
Net Profit YoY
1.4%
23.1%
EPS (diluted)
$-2.55
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
S
S
Q4 25
$321.1M
$258.9M
Q3 25
$287.3M
$242.2M
Q2 25
$212.8M
$229.0M
Q1 25
$137.3M
Q4 24
$103.3M
Q3 24
$62.2M
Q1 24
$0
Q4 23
$0
Net Profit
MDGL
MDGL
S
S
Q4 25
$-58.6M
$-60.3M
Q3 25
$-114.2M
$-72.0M
Q2 25
$-42.3M
$-208.2M
Q1 25
$-73.2M
Q4 24
$-59.4M
Q3 24
$-107.0M
Q1 24
$-147.5M
Q4 23
$-112.2M
Gross Margin
MDGL
MDGL
S
S
Q4 25
73.8%
Q3 25
75.0%
Q2 25
75.3%
Q1 25
96.7%
Q4 24
Q3 24
Q1 24
Q4 23
Operating Margin
MDGL
MDGL
S
S
Q4 25
-18.6%
-28.3%
Q3 25
-39.7%
-33.3%
Q2 25
-22.2%
-38.2%
Q1 25
-57.8%
Q4 24
-64.8%
Q3 24
-187.1%
Q1 24
Q4 23
Net Margin
MDGL
MDGL
S
S
Q4 25
-18.2%
-23.3%
Q3 25
-39.8%
-29.7%
Q2 25
-19.9%
-90.9%
Q1 25
-53.4%
Q4 24
-57.5%
Q3 24
-172.0%
Q1 24
Q4 23
EPS (diluted)
MDGL
MDGL
S
S
Q4 25
$-2.55
$-0.18
Q3 25
$-5.08
$-0.22
Q2 25
$-1.90
$-0.63
Q1 25
$-3.32
Q4 24
$-2.50
Q3 24
$-4.92
Q1 24
$-7.38
Q4 23
$-5.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
S
S
Cash + ST InvestmentsLiquidity on hand
$198.7M
$649.8M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$602.7M
$1.5B
Total Assets
$1.3B
$2.4B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
S
S
Q4 25
$198.7M
$649.8M
Q3 25
$295.7M
$810.8M
Q2 25
$186.2M
$766.9M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$232.7M
Q1 24
$622.5M
Q4 23
$99.9M
Total Debt
MDGL
MDGL
S
S
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q1 24
$116.1M
Q4 23
$115.5M
Stockholders' Equity
MDGL
MDGL
S
S
Q4 25
$602.7M
$1.5B
Q3 25
$625.7M
$1.5B
Q2 25
$696.0M
$1.5B
Q1 25
$710.6M
Q4 24
$754.4M
Q3 24
$777.2M
Q1 24
$850.8M
Q4 23
$405.3M
Total Assets
MDGL
MDGL
S
S
Q4 25
$1.3B
$2.4B
Q3 25
$1.4B
$2.4B
Q2 25
$1.0B
$2.4B
Q1 25
$996.6M
Q4 24
$1.0B
Q3 24
$1.1B
Q1 24
$1.1B
Q4 23
$640.5M
Debt / Equity
MDGL
MDGL
S
S
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q1 24
0.14×
Q4 23
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
S
S
Operating Cash FlowLast quarter
$-133.5M
$21.0M
Free Cash FlowOCF − Capex
$-133.8M
$20.9M
FCF MarginFCF / Revenue
-41.7%
8.1%
Capex IntensityCapex / Revenue
0.1%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
S
S
Q4 25
$-133.5M
$21.0M
Q3 25
$79.8M
$-1.0M
Q2 25
$-47.1M
$52.3M
Q1 25
$-88.9M
Q4 24
$-104.5M
Q3 24
$-67.0M
Q1 24
$-149.2M
Q4 23
$-79.9M
Free Cash Flow
MDGL
MDGL
S
S
Q4 25
$-133.8M
$20.9M
Q3 25
$79.0M
$-1.3M
Q2 25
$52.1M
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q1 24
$-149.5M
Q4 23
$-81.0M
FCF Margin
MDGL
MDGL
S
S
Q4 25
-41.7%
8.1%
Q3 25
27.5%
-0.5%
Q2 25
22.8%
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q1 24
Q4 23
Capex Intensity
MDGL
MDGL
S
S
Q4 25
0.1%
0.0%
Q3 25
0.3%
0.1%
Q2 25
0.0%
0.1%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

S
S

US$154.8M60%
Non Us$104.1M40%

Related Comparisons